HERTFORDSHIRE, England and
PITTSBURGH, May 4, 2020 /PRNewswire/ -- Mylan
N.V. (NASDAQ: MYL) has been working since its founding in 1961
to create access to medicine for patients, and that aspiration has
included a strong commitment to long-term thinking, sustainability
and making a positive impact. Since 2019 is currently expected to
be Mylan's last year as a standalone company, Mylan has chronicled
both its history and 2019 social responsibility milestones in its
newly published "A Legacy of Impact: 2019 Global Social
Responsibility Report."
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8094855-mylan-global-social-responsibility-gsr-report/
The report provides a comprehensive, enterprise-wide overview of
Mylan's operations as they relate to environmental, social and
governance (ESG) matters. More specifically, it includes an
overview of the company's impact over the years on access to
medicine, patients, employees, the environment, global public
health and the community and highlights its most recent efforts and
achievements in those areas.
The report's publication comes at a time when the world is
united in the fight against the COVID-19 pandemic. Mylan's focus
remains on the health and safety of its employees, while also
working to ensure supply continuity as well as support patients and
communities during this unprecedented time. The company will
continue to provide regular updates on its efforts via its
website.
"While the world around us has changed, Mylan's mission has
remained the same for almost 60 years," said Heather Bresch, CEO of Mylan. "Our passion for
delivering better health for a better world is at the core of
everything we do and has never been more important. From
establishing pathways for high quality, affordable generics and
biosimilars to our current role in continuing to help fight the
battle against COVID-19, we have been committed throughout our
history to achieving positive and sustained impact."
In 2019 alone, Mylan demonstrated this commitment by:
- Delivering ~62 billion doses of medicine across more than 165
countries and territories, including ~90% of low- and
lower-middle-income countries;
- Providing Mylan medication to ~60% of the world's HIV+ children
receiving treatment;
- Growing our renewable energy consumption by 25%;
- Becoming the first generic manufacturer to receive WHO
prequalification for a hepatitis C treatment; and
- Announcing a global partnership to increase access to
tuberculosis treatments in many low-income countries.
"A fundamental component of Mylan's operations and overall focus
is ensuring long-term, sustainable results and positive impact in
everything we do," said Lara
Ramsburg, head of Corporate Affairs at Mylan. "Combined with
the daily dedication of our workforce of approximately 35,000
people around the world, Mylan has engrained a global social
responsibility infrastructure designed to continually evolve to
meet the future ahead."
To learn more
visit http://www.mylan.com/en/social-responsibility.
Commitment to the United Nations (U.N.) Global
Compact
Mylan is a signatory to the U.N. Global Compact and
is committed to its 10 principles aimed at protecting human rights
and the environment and ensuring fair labor and corruption-free
business practices. The Global Social Responsibility 2019 Progress
Report constitutes Mylan's Communication on Progress Report.
Support of the Sustainable Development Goals
(SDGs)
The Sustainable Development Goals (SDGs), adopted by
all U.N. Member States in 2015, form the basis for collectively
creating a better future by addressing fundamental global
challenges such as poverty, poor health, inequality and climate
change, among others. Mylan supports this agenda and recognizes
that companies must play a central role in helping to achieve these
development goals.
Good Health and Well-Being (3) is the goal where we can have our
most significant positive impact. Mylan's mission, our broad and
diverse portfolio across ten key therapeutic areas – combined with
our long-standing commitment to increasing access to high quality
medicine through innovation, expansion and partnerships – strongly
positions Mylan to make continued contributions toward this
goal.
About Mylan
Mylan is a global pharmaceutical company
committed to setting new standards in healthcare. Working together
around the world to provide 7 billion people access to high quality
medicine, we innovate to satisfy unmet needs; make reliability and
service excellence a habit; do what's right, not what's easy; and
impact the future through passionate global leadership. We offer a
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which approximately 40% of
people being treated for HIV/AIDS globally depend. We market our
products in more than 165 countries and territories. We are one of
the world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com.
Forward-Looking Statements
This press release
includes statements that constitute "forward-looking statements,"
including with regard to 2019 currently being expected to be
Mylan's last year as a standalone company; the potential impact of
COVID-19 and Mylan's role in continuing to help fight the battle
against COVID-19; and Mylan's focus remaining on the health and
safety of its employees, while also working to ensure supply
continuity as well as support patients and communities during this
unprecedented time. Because forward-looking statements
inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such
statements. Factors that could cause or contribute to such
differences include, but are not limited to; the potential
widespread and highly uncertain impact of public health outbreaks,
epidemics and pandemics, such as the COVID-19 pandemic; any changes
in, interruptions to, or difficulties with Mylan's or its partners'
ability to develop, manufacture, and commercialize products; the
effect of any changes in Mylan's or its partners' customer and
supplier relationships and customer purchasing patterns; other
changes in third-party relationships; the impact of competition;
changes in the economic and financial conditions of the businesses
of Mylan or its partners; the scope, timing, and outcome of any
ongoing legal proceedings and the impact of any such proceedings on
Mylan's or its partners' business; any regulatory, legal, or other
impediments to Mylan's or its partners' ability to bring products
to market; actions and decisions of healthcare and pharmaceutical
regulators, and changes in healthcare and pharmaceutical laws and
regulations, in the United States
and abroad; Mylan's and its partners' ability to protect
intellectual property and preserve intellectual property rights;
risks associated with international operations; other uncertainties
and matters beyond the control of management; and the other risks
detailed in Mylan's filings with the Securities and Exchange
Commission. Mylan undertakes no obligation to update these
statements for revisions or changes after the date of this
release.
View original
content:http://www.prnewswire.com/news-releases/mylan-releases-a-legacy-of-impact-2019-global-social-responsibility-report-301052034.html
SOURCE Mylan N.V.